Manhattan Scientifics, Azano Biotech collaborate to commercially introduce NanoMRX nanoparticles

Senior Scientific, a division of Manhattan Scientifics, has manufactured nanoparticles primarily to support its NanoMRX cancer detection technology. Now the company is making them available for other applications.

In collaboration with Azano Biotech, NanoMRX precision nanoparticles are now available for cell separation, targeted therapy, MRI contrast, magnetic particle imaging.

This is the first time these nanoparticles will be made available for use outside of Senior Scientific’s own programs.

According to Manhattan Scientifics, the NanoMRX nanoparticles are uniquely precise and reproducible for consistent results. These nanoparticles are manufactured to a precision not available with other iron oxide nanoparticles on the market.

The NanoMRX nanoparticles are provided in sizes from 5-30nm, with a variation of only +/- 0.5nm. For discriminating researchers and precise applications, the nanoparticles will remove experimental variability normally associated with nanoparticles and improve results.

Azano Biotech CEO Michael Perrine noted the company is eager to make Senior Scientifics’ high precision nanoparticles available to the industry.

"We anticipate applications in separation, targeting, MRI contrast and Magnetic Particle Imaging (MPI)," Perrine added.

Senior Scientific’s NanoMRX technology uses non-toxic NanoMRX iron oxide nanoparticles and ultrasensitive magnetic detection for a highly sensitive and very specific approach to cancer detection that can locate and measure tumors one millionth the size detectable by X-Rays and MRI.